Osavampator not checked
Neurocrine Biosciences · NBI-1065845 · TAK-653
FollowEvery change as it happens, and a Monday email
Trials
5 active
8 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Major Depressive Disorder (5 trials)
- Main trialPhase 3
- “The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.”In the company’s words, NCT06963021 on ClinicalTrials.gov
- Other names
- NBI-1065845 · TAK-653
Other drugs for Major Depressive Disorder
- SeltorexantJanssen Research & Development, LLC · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- DT120Definium Therapeutics US, Inc. · Phase 3
Coming up5
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2027 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | |
| Phase 3Recruiting | Jul 2027 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | |
| Phase 3Recruiting | Jul 2027 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | |
| Phase 3Recruiting | Jul 2028 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | |
| Phase 3Recruiting | May 2029 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | |
| Phase 2Completed | 10 Jan 2024 | Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) | |
| Phase 1Completed | 11 Sep 2017 | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants | |
| Phase 1Completed | 15 May 2019 | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026